Anika Therapeutics, Inc. ANIK, a leader in products for tissue
protection, healing and repair, based on hyaluronic acid (HA) technology,
today announced that it has filed regulatory submissions in both the United
States and Europe seeking the approval of Cingal, the Company's novel HA plus
steroid single-injection treatment for osteoarthritis of the knee. Anika
submitted its application for CE Mark approval to commercialize Cingal in the
European Union and also filed its premarket approval application (PMA) with
the U.S. Food and Drug Administration to allow for marketing and distribution
in the United States.
"After meeting all of the primary and secondary endpoints from our
multinational Phase III Cingal clinical trial in a clinically and
statistically meaningful fashion, we filed the CE Mark application as planned
at the end of 2014 and submitted the PMA a few days ago, ahead of schedule,"
said Anika President and CEO Dr. Charles H. Sherwood. "The filing of these
submissions is a milestone achievement for Anika and, after approvals,
positions us extremely well in the market from a competitive standpoint. In
addition to the United States and Europe, we plan to commercialize Cingal in
other key markets in the world. We look forward to patients benefiting from
Cingal, which provides the convenience and efficacy of our current
single-injection treatment, Monovisc^®, with the added early symptom relief
benefits of a commonly used steroid."
The Cingal Phase III trial was a 26-week, randomized, double-blind, three-arm,
placebo-controlled study designed to evaluate the efficacy and safety of a
single injection of Cingal in approximately 368 patients experiencing joint
pain from osteoarthritis of the knee who had not responded to conservative
treatment. Patients were randomized to receive a Cingal treatment, a placebo
treatment or a treatment of Anika's Monovisc product. After the initial
treatment, patients were assessed for 26 weeks at clinical sites in Europe and
Canada. The primary clinical effectiveness endpoint data measured the change
in the patients' knee pain over the course of the trial from their baseline
level according to the WOMAC Pain Score.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in